drugset
drugset / Trial / NCT06315010

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

NCT06315010 ↗

Phase 2 Recruiting 20 enrolled MedSIR Medical University of Vienna · collab
NaSingle-groupOpen-labelTreatment

Summary

REPOSE is a phase II clinical trial exploring the safety and efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) characterized by the presence of brain metastasis (BM) and whose tumors have mutated ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene.

Timeline

Start
2025-06-27
Primary completion
2027-03
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Repotrectinib Small molecule 160 mg Oral

Indications

metastatic malignant neoplasm in the brain non-small cell lung carcinoma